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A DNA-binding factor with properties of NF-KB and another similar activity are rapidly induced when
growth-arrested BALB/c 3T3 ceUs are stimulated with serum growth factors. Induction of these DNA-binding
activities is not inhibited by pretreatment of quiescent ceUs with the protein synthesis inhibitor cycloheximide.
Interestingly, the major NF-KB-like activity is not detected in nuclear extracts of proliferating ceUs, and thus
its expression appears to be limited to the Go-to-G1 transition in 3T3 ceUs. These DNA-binding activities bind
many of the expected NF-cB target sequences, including elements in the class I major histocompatibility
complex and human immunodeficiency virus enhancers, as weUl as a recently identified NF-cB binding site
upstream of the c-myc gene. Furthermore, both the class I major histocompatibility complex and c-myc NF-KcB
binding sites confer inducibility on a minimal promoter in 3T3 cells stimulated with serum growth factors. The
results demonstrate that NF-KB-like activities are immediate-early response proteins in 3T3 cells and suggest
a role for these factors in the Go-to-G1 transition.
Much of our knowledge concerning the signals that are
activated following the interaction of serum growth factors
with their receptors and that are involved in the stimulation
of cell growth has been generated by using serum-deprived
BALB/c 3T3 fibroblasts. In the absence of serum growth
factors, 3T3 cells enter a state called Go in which growth and
cell division stop. The addition of growth factors initiates a
complex series of events which causes cells to enter G1 and
which culminates in the synthesis of DNA and cell division
(1, 13, 15, 16, 18, 29, 41). During the GO-to-G1 transition, the
expression of several transcription factors, including those
encoded by certain proto-oncogenes, is activated, and these
gene products play a critical role in initiating and controlling
cell growth and DNA synthesis (13, 15-18, 28, 32, 38, 41, 48,
50, 58, 64). Aberrant expression of these proto-oncogenes,
such as c-fos or c-myc, is implicated in the pathogenesis of a
variety of neoplasms (21, 39).
NF-KB is a DNA-binding protein originally identified as a
B-cell-specific factor involved in the control of expression of
immunoglobulin kappa genes (59). Subsequently, regulatory
elements in or upstream of various genes involved in im-
mune function or in inflammation and elements in certain
viruses such as the human immunodeficiency virus (HIV)
have been shown to interact with NF-KB and to be critical
for appropriate regulated or cell-type-specific gene expres-
sion (7, 11, 20, 23, 30, 34, 42, 43, 45, 49, 53, 55, 67). NF-KB
DNA-binding activity can be induced in certain cell types
with the cytokines tumor necrosis factor alpha and interleu-
kin-1 (34, 42, 46, 52, 61), with the phorbol ester phorbol
myristate acetate (PMA) (60), by virus infection, and by
double-stranded RNA treatment (23, 42, 43, 67). Further-
more, NF-KB DNA-binding activity is activated by treat-
ment of pre-B cells and Jurkat T cells with mitogens (11, 20,
49, 60). Thus NF-KB acts as an intracellular messenger
affecting specific gene expression. NF-KB is cytoplasmically
localized in many cells, where it is associated with the
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inhibitor IKB (2, 3, 69). Purified NF-KB consists of two
proteins, one of 50 kDa and another of 65 kDa. It is the
65-kDa species that interacts with the inhibitor IKB (3, 66).
Phosphorylation of IKB releases NF-KB from the complex,
allowing its movement to the nucleus and the detection of its
DNA-binding activity (26, 62). Recently both the NF-KB p50
and p65 cDNAs have been cloned, and the deduced proteins
have been shown to be related to the products of the dorsal
maternal effect gene of Drosophila melanogaster and to the
c-rel proto-oncogene (27, 40, 51, 56). Furthermore, NF-KB
and the DNA-binding protein KBF1 (33), which bind highly
related sites, have apparently identical 50-kDa DNA-binding
subunits (27, 40).
We demonstrate here that NF-KB nuclear DNA-binding
activity, or that of a highly related factor, is induced when
quiescent BALB/c 3T3 cells are stimulated with serum
growth factors. Interestingly, we do not detect any NF-KB
binding activity in nuclear extracts of proliferating cells,
suggesting that the relatively high levels of expression of
NF-KB DNA-binding activity is specific for the Go-to-G1
transition in 3T3 cells. In addition, we demonstrate that a
second NF-KB-like DNA-binding activity is also induced in
the Go-to-G1 transition that, in contrast with NF-KB, is
detected in nuclear extracts of proliferating 3T3 cells. The
inducible NF-KB-like activities have the binding specificity
expected of authentic NF-KB and also bind a recently
described (22) NF-KB site found upstream of the c-myc gene.
Furthermore, the NF-KB binding sites found in the class I
major histocompatibility complex (MHC) enhancer and up-
stream of the c-myc gene function as inducible gene expres-
sion elements when quiescent 3T3 cells are stimulated with
serum growth factors. These results suggest a role for
NF-KB in the Go-to-G1 transition in 3T3 cells.
MATERIALS AND METHODS
Cells and nuclear extracts. Low-passage BALB/c 3T3 cells
were maintained in Dulbecco modified Eagle medium
(DMEM) plus 10% Colorado calf serum. For generation of
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nuclear extracts, cells were grown to an approximate density
of 50 to 70% and then maintained in DMEM plus 0.5%
Colorado calf serum for approximately 48 h. Colorado calf
serum was added to 20% final volume, and the cells were
maintained for various periods of time before nuclear ex-
tracts were prepared. For the protein synthesis inhibition
experiments, cycloheximide was added to a final concentra-
tion of 10 jig/ml for 1 h prior to the addition of serum to the
medium and remained in the medium during the serum
stimulation. Jurkat T cells were grown in RPMI 1640 me-
dium and 10% fetal calf serum. For stimulation of Jurkat T
cells, phytohemagglutinin (PHA) and PMA were added to
final concentrations of 1 jig/ml and 50 ng/ml, respectively.
Nuclear extracts were prepared as previously described (65).
DNA binding assays and methylation interference. To de-
tect DNA-protein interaction, the gel mobility shift assay (4,
24) was used. Nuclear extracts (approximately 6 ,ug for each
extract) were incubated with a radiolabeled DNA probe
(10,000 cpm/0.2 ng) in a buffer containing 10 mM Tris-HCl
(pH 7.9), 50 mM NaCl, 0.5 mM EDTA, 10% glycerol, 1 mM
dithiothreitol, and 2 ,ug of poly(dI-dC) - (dI-dC) (Pharmacia)
in a final volume of 15 ,ul. Reactions were incubated at room
temperature for approximately 20 min and then loaded onto
5% polyacrylamide gels and electrophoresed in a Tris-
glycine-EDTA buffer (4). For the inhibition studies, IKB/
MAD-3 mRNA was translated in reticulocyte lysates as
described previously (31). Reticulocyte lysates that were
either programmed with IKB/MAD-3 mRNA or mock trans-
lated were preincubated with nuclear extracts from 3T3 cells
stimulated with serum for 2 h. Subsequently poly(dI-
dC)- (dI-dC) and class I MHC enhancer probe were added.
The reactions were analyzed as described above. Gels were
dried and exposed for autoradiography.
DNA probes used in the experiments were HindIII-EcoRI
fragments derived from pUC polylinkers with oligonucleo-
tides for the various binding sites cloned into the BamHI
site. Following restriction enzyme digestions of the plas-
mids, the restriction fragments were labeled with the Kle-
now fragment of DNA polymerase I and [a-32P]dATP as
described previously (6). Radiolabeled probes were isolated
on 1.5% low-melting-temperature agarose gels. The adeno-
virus major late transcription factor (MLTF) binding site is
ACCCGGTCACGTGGCCTACA (14). The various NF-KB
binding sites are as follows: class I MHC, TGGGGATTCC
CCA; 2-microglobulin, AAGGGACTTTCCC; kappa immu-
noglobulin light chain, AGGGGACTTTCCG; HIV (4G),
TGGGGACTTTCCA; HIV (3G), AAGGGACTTTCCG; and
c-myc, CCGGGTTTTCCCC. The MHC double-point mu-
tant is TGCGGCTTCCCGA.
Methylation interference was performed as described (7),
using a DNA-binding probe from the class I MHC enhancer
that was labeled at a single end and that was methylated with
dimethyl sulfate. To generate the single-end-labeled probe,
the class I MHC enhancer-containing plasmid was cut and
labeled at either the HindlIl or the EcoRI site and then
digested with the other enzyme. Following recovery of the
free probe and the bound DNA-protein complexes obtained
from gel shift separation, the methylated DNA probe was
cleaved with piperidine, electrophoresed on a 6% polyacryl-
amide-7.5 M urea gel, and exposed for autoradiography.
Transient expression analysis. BALB/c 3T3 cells were
transfected by either calcium phosphate precipitation or
electroporation procedures. Reporter plasmids were the
following: A56 CAT, a minimal fos promoter extending to
-56 fused to the bacterial chloramphenicol acetyltransferase
(CAT) gene (28); MHC-NF-KB CAT, with three copies of the
class I MHC enhancer element TGGGGATTCCCCA in-
serted in the SalI site of A56CAT; MHCmut-NF-KB CAT,
with three copies of the mutated enhancer sequence TGCG
GATTCCCGA inserted in the Sall site of A56CAT; and
myc-NF-KB CAT, with either two copies (2x) or one copy
(lx) of the c-myc NF-KB binding site CCGGGTTTTCCCC
inserted at the SalI site of A56 CAT (see Fig. 5C for diagrams
of the constructs). Cells transfected by the calcium phos-
phate procedure were seeded 24 h prior to transfection at 8
x 105 cells per 10-cm dish. A precipitate containing 10 ,ug of
DNA was left on the cells overnight, followed by glycerol
(12.5% volume) shock. For electroporation, 4 x 106 cells
were transfected with 10 jig ofDNA in a volume of 0.5 ml of
DMEM plus 10% fetal calf serum at 300 V and 960 ,uF.
Electroporated cells were left overnight to reattach. For
both procedures, the cell culture medium was changed to
0.5% serum 16 to 18 h after transfection and cells were
maintained for 24 h. Half of the cells received 20% serum
(final volume), and both the serum-starved and serum-
stimulated cells were maintained for an additional 24 h.
Extracts were prepared for CAT analysis as described
previously (65). Equal volumes of extracts of starved or
stimulated cells, representing an equivalent numbers of cells
that were initially transfected, were assayed for CAT activ-
ity by thin-layer chromatography. The thin-layer chromatog-
raphy plates were exposed for autoradiography for approx-
imately 24 h. The results presented are from a typical
experiment; virtually identical results were obtained in six
different transfections using either calcium phosphate pre-
cipitation or electroporation.
RESULTS
Identification of serum growth factor-inducible DNA-bind-
ing activities. Since NF-KB has been shown to be inducible
by mitogen treatment of pre-B and Jurkat T cells and by
PMA treatment of a variety of cell types (11, 49, 60), we
chose to analyze whether NF-KB could be induced by serum
growth factor treatment of quiescent 3T3 cells. BALB/c 3T3
cells were grown to an approximate density of 50 to 70% and
were serum starved for 48 h. Serum was added to a final
concentration of 20% for some of the tissue culture plates at
different time points, while others remained in 0.5% serum.
Cells were collected at the various time points, and nuclear
extracts were prepared. The DNA-binding properties of the
nuclear extracts were assayed by the gel mobility shift
procedure using a radiolabeled class I MHC enhancer ele-
ment probe, containing the sequence TGGGGATTCCCCA,
previously shown to bind to NF-KB (7). Equal amounts of
protein from the different time points were incubated with
the MHC probe, and the reactions were analyzed on nonde-
naturing polyacrylamide gels. Figure 1A (lanes 1 and 2)
demonstrates that nuclear extracts of quiescent 3T3 cells are
relatively devoid of DNA-binding activity and that a major
DNA-protein complex (complex I) was detected following
only 30 min of serum growth factor stimulation. Analysis of
the nuclear extracts from the different time points revealed
that this major complex was detected at relatively high levels
at time points 30 min, 2 h, and 6 h (lanes 2 to 4) following
addition of serum growth factors. The 12- and 24-h time
points demonstrated significantly reduced levels of this
DNA-protein complex (lanes 5 and 6). Also detected were
two faster-migrating complexes (complexes II and III; Fig.
1A). Complex II is present in quiescent cells and appeared to
gradually increase during the time course of stimulation (Fig.
1A). Complex III was shown to be induced by growth factor
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FIG. 1. Analysis of serum growth factor-inducible DNA-binding proteins. (A) Gel mobility shift analysis of nuclear extracts from quiescent
and serum-stimulated 3T3 cells, using a class I MHC enhancer element probe (see Materials and Methods for the sequence of the probe).
Equivalent amounts of the following extracts were used: quiescent cells (lane 1) and cells stimulated with serum for 30 min (lane 2), 2 h (lane
3), 6 h (lane 4), 12 h (lane 5), and 24 h (lane 6). Lanes 7 to 10 exhibit a separate experiment analyzing the effects of cycloheximide on the
inducibility of the DNA-binding proteins. Proteins were from extracts of quiescent 3T3 cells (lane 7), cells stimulated with serum for 30 min
(lane 8), or 2 h (lane 9), or cells that were pretreated with cycloheximide for 1 h and then given serum for an additional 2 h (lane 10). Complexes
I, II, and III are indicated. (B) Normalization of extracts using an MLTF binding site probe (see Materials and Methods). Lanes correspond
to lanes 1 to 6 in panel A.
stimulation and remained relatively high through the 12-h
time point but was significantly reduced by the 24-h time
point (Fig. 1A, lanes 1 to 6). Virtually identical DNA-binding
results were obtained for extracts of BALB/c 3T3 cells
stimulated with sis-conditioned medium (5), suggesting that
platelet-derived growth factor is capable of inducing these
DNA-binding activities.
We next determined whether the induction of these factors
required protein synthesis. We pretreated serum-starved
3T3 cells with cycloheximide for 1 h and then stimulated the
cells, in the presence of cycloheximide, with serum for 2 h.
As controls, cells stimulated with serum growth factors for
30 min and 2 h in the absence of cycloheximide were
analyzed. As shown in Fig. 1A (lanes 7 to 9), the pattern of
induction for the quiescent, 30-min, and 2-h extracts was
virtually identical to that presented in lanes 1 to 3. Further-
more, cycloheximide did not prevent and may actually have
stimulated expression of the major DNA-binding factor
(complex I) and the complex III factor as well, but it reduced
complex II (lane 10). That the cycloheximide functioned to
block protein synthesis is demonstrated by the observation
that the induction of another serum growth factor-inducible
DNA-binding protein was inhibited (70).
To demonstrate that the various extracts contained the
normal complement of DNA-binding proteins, the 3T3 nu-
clear extracts from the different time points were incubated
with a radiolabeled probe for the MLTF (14) (also known as
USF) binding site in the adenovirus major late promoter
(Fig. 1B, lanes 1 to 6). The DNA-binding activity of this
factor is approximately the same for the different time
points, demonstrating that the extracts are not degraded and
that similar amounts of protein were used in the different
binding reactions.
Properties of the major inducible factor are virtually iden-
tical to those of NF-KB. The major inducible factor (associ-
ated with complex I) binds the class I MHC element and is
inducible in the presence of cycloheximide (Fig. 1A, lanes 7
to 10). Since these properties are characteristic of NF-KB (7,
60), we next analyzed the binding specificities of the serum
growth factor-induced DNA-binding factors. As shown in
Fig. 2A (lanes 1 to 5), the major inducible factor binds with
approximately equal affinity to related regulatory elements
found upstream of the class I MHC, ,32-microglobulin, and
HIV genes and in the enhancer of the immunoglobulin kappa
light-chain gene. This result is consistent with the growth-
inducible factor being similar or identical to NF-KB (42).
While this work was in progress, it was reported that
NF-KB-like factors found in WEHI 231 B cells bind to an
element located approximately 1,100 bp upstream of the
c-myc gene (22). Since c-myc transcription is activated in the
Go-to-G1-transition in 3T3 cells (29, 38), we tested whether
the inducible NF-KB activity binds to this sequence. The
major inducible 3T3 factor binds to the CCGGGTTTTCCCC
element upstream of the c-myc gene with an affinity similar
to, although possibly lower than, that of the other identified
NF-KB sites (Fig. 2A, lane 6). The factors associated with
the constitutive complex II and with the inducible complex
III bind to these various sites with an affinity similar to that
of the slower, more prominent factor (complex I), although
the complex II factor appears weaker for the immunoglobu-
lin kappa probe (lane 3). All three factors are specific in their
interaction with the various regulatory elements since they
do not bind a double-point-mutated class I MHC enhancer
probe (lane 7).
We next compared the mobility of the inducible 3T3
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FIG. 2. The serum-inducible factors have properties of NF-KB.
(A) Gel mobility shift analysis using nuclear extracts from 3T3 cells
stimulated for 2 h with serum. Probes are MHC (lane 1), IP2-
microglobulin (lane 2), immunoglobulin kappa (lane 3), HIV 4G
(lane 4), HIV 3G (lane 5), c-myc (lane 6), and MHC double-point
mutant (lane 7). See Materials and Methods for the sequences of the
various probes. (B) Comparison of serum growth factor-induced 3T3
complexes with factors induced by mitogen and phorbol ester
treatment of Jurkat T cells. All lanes have the class I MHC enhancer
probe. Extracts are 2-h serum-stimulated 3T3 cells (lane 1), unin-
duced Jurkat T cells (lane 2), and Jurkat T cells stimulated for 2 h
with PHA and PMA (lane 3). (C) Inhibition of DNA-binding activity
by IKB, as determined by gel mobility shift analysis using nuclear
extracts from 3T3 cells stimulated for 2 h with serum and using the
class I MHC probe. Lanes: 1, no reticulocyte lysate added; 2,
reticulocyte lysate programmed with MAD-3/IKB mRNA (31); 3,
mock-translated lysates. Complexes I, II, and III are indicated.
line by phorbol ester (PMA) and mitogen (PHA) stimulation.
PMA and PHA treatment of Jurkat T cells has been shown to
induce NF-KB binding activity (11, 49). As shown in Fig. 2B
(lanes 1 and 3), the pattern of binding of the extracts of
induced Jurkat cells is virtually identical to that of the




FIG. 3. (A) Methylation interference of the serum-inducible 3T3
complexes. The class I MHC enhancer probe was labeled at either
the HindIll or EcoRI end and methylated as described in Materials
and Methods. This probe was used in gel mobility shift analysis with
extracts of 3T3 cells that were stimulated with serum for 2 h.
Complexes I and III and the free probe were cut out of the gel. DNA
was recovered, cleaved with piperidine, and electrophoresed on
polyacrylamide sequencing gels. The bottom and the top stands are
shown, each with cleaved free probe and cleaved complexes I and
III. (B) Sequence of the binding site. Guanines that interfere with
binding are indicated with asterisks.
cases, nuclear extracts were used from cells that had been
stimulated for 2 h with either serum growth factors (3T3
cells) or PMA and PHA (Jurkat cells). Similarly, binding
specificities of the induced Jurkat and 3T3 factors are also
identical (5). The factor associated with the inducible 3T3
complex III is specific, has many properties in common with
NF-KB (Fig. 1A and 2A), and has a gel shift mobility similar
to that of purified KBF1 (5).
To further relate the inducible 3T3 factors with NF-KB, we
determined whether a recently identified IKB activity (31)
could inhibit their DNA-binding activities. This IKB-like
activity, MAD-3, inhibits the DNA-binding activity of
NF-KB but not that of KBF1, MLTF, Oct-i, or H2TF1 (31).
In vitro-translated MAD-3 specifically inhibited the DNA-
binding activity of the inducible factors associated with
complexes I and III but not that associated with complex II
(Fig. 2C, lanes 1 to 3). Mock-translated reticulocyte lysates
nonspecifically inhibited the formation of complex II (lane 3)
but did not block formation of complexes I and III. These
results demonstrate that the serum-inducible factors associ-
ated with complexes I and III are NF-KB-like.
To determine which nucleotides in the class I MHC
enhancer element are capable of close interaction with the
induced 3T3 factors, methylation interference analysis was
performed on the complexes I and III. The methylated class
I MHC enhancer probe was used in a gel shift reaction with
extracts of 3T3 cells that had been serum stimulated for 2 h.
Piperidine cleavage ofDNA isolated from bands I and III in
comparison with that of the free DNA probe revealed (Fig.
3) that methylation of all guanines in the symmetrical class I
MHC enhancer element interfered with the binding of the
A
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FIG. 4. Comparison of nuclear extracts of proliferating, quies-
cent, and serum-stimulated 3T3 cells, using gel mobility shift anal-
ysis. Lanes 1 to 3, class I MHC enhancer probe; lanes 4 and 5,
MLTF probe. Equivalent amounts of the following extracts were
analyzed: proliferating 3T3 cells (lanes 1 and 4), quiescent 3T3 cells
(lane 2), and 3T3 cells serum stimulated for 2 h (lanes 3 and 5). The
mobilities of complexes I, II, and III are indicated.
factors. Thus, the methylation interference patterns for
complexes I and III are identical. These results are consis-
tent with our previously published methylation interference
pattern of NF-KB from lipopolysaccharide (LPS)-treated
pre-B cells on the MHC element (7), although no partial
interference is seen with the 3T3 complexes on the external
guanines (Fig. 3).
Expression of the major NF-KB-like DNA-binding activity is
specific for the GO-to-G, transition in 3T3 cells. To determine
whether NF-KB binding activity could be detected in prolif-
erating 3T3 cells and whether its expression is independent
of Go, a nuclear extract was prepared from BALB/c 3T3 cells
that were at an approximate density of 50 to 70% and were
growing in fully supplemented medium. This extract was
used in a gel mobility shift experiment in comparison with
extracts of quiescent cells and 3T3 cells stimulated with
serum for 2 h. As shown in Fig. 4 (lane 1), no NF-KB
DNA-binding activity (complex I) is detected in the prolif-
erating cells. However, complexes II and III are readily
detected in these extracts. Levels of the MLTF binding
activity are similar between proliferating 3T3 cells and cells
stimulated with serum for 2 h (lanes 4 and 5), serving to
normalize the extracts. The quiescent cells demonstrate a
small amount of the NF-KB activity, and the serum-induced
extracts contain a relatively large amount of the activity
(lanes 2 and 3), as previously demonstrated. Lanes 1 to 3
were autoradiographed for 48 h in order to determine
whether NF-KB DNA-binding activity could be detected.
We reproducibly detect a small amount of the NF-KB like
activity in the quiescent cell extracts (Fig. 1A, lanes 1 and 7;
Fig. 4, lane 2), and this may represent a GO-specific form of
the binding activity or leakiness of some of the cells to enter
G1 once they have been maintained in Go. The demonstra-
tion that nuclear extracts of proliferating 3T3 cells contain no
detectable NF-KB binding activity is consistent with the
study of Sen and Baltimore (59). Cytoplasmic extracts of
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FIG. 5. Transient expression analysis in quiescent and serum-
stimulated 3T3 cells transfected with CAT reporter plasmids. The
CAT analysis presented is from a typical calcium phosphate copre-
cipitation experiment that has been reproduced in six experiments.
(A) Expression analysis using plasmids MHC-NF-KB CAT, MHC-
mut-NF-KB CAT, and A56 CAT, as indicated, in the absence of
serum (-) and after serum stimulation (+). (B) Expression analysis
using myc-NF-KB CAT (2x) or (lx) or A56 CAT, as indicated, in
the absence (-) or presence (+) of serum. (C) Diagrams of the
plasmid constructs used in the transfections. Open boxes represent
wild-type MHC or c-myc NF-KB binding sites; an X within a box
represents a double-point mutant. For transfection procedures,
details of cell maintenance, and descriptions of plasmids, see
Materials and Methods.
proliferating 3T3 cells contain a detergent-activatable NF-KB
that gives a complex identical in mobility to complex I (5).
Thus, proliferating 3T3 cells appear to have NF-KB DNA-
binding activity, but virtually none of the DNA-binding
activity is localized in the nucleus. The extracts of prolifer-
ating 3T3 cells contain a factor with properties of complex
III (Fig. 4, lane 1). These results demonstrate that the levels
of the NF-KB-like activity induced in the Go-to-G1 transition
are not reproduced in cycling 3T3 cells. We cannot rule out
the possibility that NF-KB binding activity is expressed at
low levels in these cells. Furthermore, the DNA-binding
activity associated with complex III is inducible in the
Go-to-G1 transition (Fig. IA), falls 12 to 24 h following serum
stimulation of quiescent cells (Fig. 1A, lanes 5 and 6), is
detected in the proliferating 3T3 cells (Fig. 4, lane 1), and
may therefore be cell cycle regulated.
The class I MHC enhancer and c-myc NF-KB binding sites
function as serum growth factor-inducible gene expression
elements. To determine whether the inducible factors are
capable of regulating gene expression mediated through the
class I MHC NF-KB binding site, we performed transient
expression experiments in serum-starved and serum-stimu-
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lated 3T3 cells. We used plasmids containing three copies of
the class I MHC enhancer element (TGGGGATTCCCCA)
upstream of a minimal fos promoter (A56 CAT, containing
promoter elements to -56 [28]) fused to the bacterial CAT
gene (MHC-NFKB-CAT) or containing three copies of the
double-point-mutated MHC element (TGCGGATTCCCGA)
in the identical position of A56CAT (MHCmut-NFKB-CAT).
BALB/c 3T3 cells were transfected with either A56CAT,
MHC-NFKB-CAT, orMHCmut-NFKB-CAT. Following trans-
fection, the cells that received each plasmid were serum
deprived for 24 h. Subsequently half of these plates received
serum (20% final volume) for an additional 24 h, while the
others remained in 0.5% serum. Extracts were prepared and
tested for CAT activity (Fig. 5). The A56 CAT construct
gave extremely low CAT activity in both the serum-starved
and serum-stimulated cells (Fig. 5A). MHC-NF-KB CAT,
with three copies of the wild-type MHC element, demon-
strated higher levels of expression than did A56 CAT in
serum-deprived cells (Fig. 5A). Addition of serum resulted in
an approximately 20- to 30-fold stimulation of CAT activity.
The MHCmut-NF-KB CAT (mutated) was virtually inactive
in both serum-deprived and serum-stimulated cells (Fig. SA),
demonstrating that a mutated MHC element that cannot bind
the inducible NF-KB activity cannot function as a serum
growth factor-inducible element for gene expression. We
next determined whether the upstream NF-KB site in c-myc
(22) could function as a serum growth factor-inducible site.
Plasmids containing either two copies or one copy of the
CCGGGTTTTCCCC element were tested in serum-deprived
and serum-stimulated 3T3 cells as described above. Both the
CAT plasmid containing two copies (myc-NF-KB 2 x) and
the plasmid containing one copy (myc-NF-KB 1x) of the myc
site were induced by serum growth factor treatment (Fig.
5B). The 2 x plasmid demonstrated higher basal activity than
did the lx plasmid. These results demonstrate that the
c-myc NF-KB binding site functions as a serum growth
factor-inducible element when combined with a heterolo-
gous promoter. Virtually identical gene expression results
were obtained with use of either calcium phosphate precip-
itation or electroporation procedures (5). The results shown
are those of a typical experiment; virtually identical results
have been obtained in six different experiments. Since there
are only two nucleotide differences in the wild-type and
mutated regulatory elements cloned upstream of the fos
promoter, it seems likely that the enhanced expression
detected with the class I MHC enhancer is mediated by
transcriptional stimulation. The slightly elevated levels of
basal expression of MHC-NF-KB CAT and myc-NF-KB CAT
in the quiescent cells (Fig. 5A and B) are consistent with the
presence of specific transcriptional regulatory proteins in
growth-arrested cells. As shown in Fig. 1A, there are such
candidate proteins in extracts of quiescent cells, and the
potential for undetected regulatory factors exists as well.
The data demonstrate that the class I MHC enhancer and
c-myc NF-KB binding sites function as inducible elements in
the Go-to-G1 transition when linked to a minimal promoter.
DISCUSSION
Serum growth factors regulate a variety of cellular pro-
cesses, including growth and differentiation (13, 18). In
growth-arrested 3T3 cells, one of the first cellular responses
to the addition of serum growth factors is the rapid transcrip-
tional activation of a set of specific genes (1, 15, 16, 18, 41,
64). These immediate-early genes are characterized by their
inducibility in the presence of protein synthesis inhibitors.
Thus, the activators of expression of immediate-early genes
are factors that preexist in quiescent cells. Among the
immediate-early genes are the members of the fos and jun
families, c-myc, and genes encoding several zinc finger-
containing proteins (15, 17, 29, 38, 48, 58, 64), all of which
are known or suspected transcription factors. Furthermore,
it has been demonstrated that the majority of primary
response genes in 3T3 cells are also expressed in T cells
treated with mitogen (20, 71). Thus, the primary response to
growth factors or mitogens likely involves the expression of
many of the same genes regardless of the cell type induced.
Deregulated expression of some of these genes, such c-fos,
c-jun, or c-myc, is strongly implicated in neoplastic transfor-
mation (21, 39).
The experiments presented here demonstrate that factors
with properties of NF-KB are transiently induced in quies-
cent BALB/c 3T3 cells by addition of serum growth factors
(Fig. 1A). Previous experiments have shown that NF-KB
DNA-binding activity is detected constitutively only in B
cells and in monocytes (30, 59). Furthermore, it has been
shown that NF-KB is induced upon mitogenic activation ofT
and pre-B cells (11, 20, 49, 60). The demonstration that
NF-KB exists in a wide range of cells in a cytoplasmically
inactive form (2) and the identification of functional NF-KB
binding sites in genes not expressed specifically in B or T
cells or in monocytes (7, 22, 23, 42) is consistent with a
diversified role for this factor. Our demonstration that serum
growth factor treatment of quiescent 3T3 fibroblasts induced
NF-KB-like activities suggests a role for these factors in the
growth response of 3T3 cells. Data presented here are
consistent with this role being in the transition from Go to
G1. Furthermore, these DNA-binding activities are rapidly
induced by serum growth factors and are induced in the
presence of cycloheximide (Fig. 1A). This result demon-
strates that the NF-KB-like activities are immediate-early
response factors in 3T3 cells. Interestingly, preliminary data
suggest that NF-KB mRNA levels are also induced by serum
growth factor treatment of quiescent 3T3 cells, but with
kinetics slower than for the induction of the DNA-binding
activity (35). It has recently been demonstrated that mitoge-
nic activation of T cells results in significant increases of p50
NF-KB mRNA (12).
The major serum-inducible factor that we detect is identi-
cal to NF-KB in binding specificity and comigrated in the gel
mobility shift assay with NF-KB induced in Jurkat T cells
and in 70Z pre-B cells (Fig. 2A and B and data not shown).
Consistent with the major inducible activity being NF-KB is
the observation that an IKB-like activity (31) inhibited its
DNA-binding activity (Fig. 2C). IKB has been previously
shown to inhibit the binding of NF-KB through interaction
with the p65 subunit (3, 66). Methylation interference of the
major inducible factor is similar to that published for NF-KB
binding to the class I MHC enhancer element, although we
have noted previously that the external guanines of the class
I MHC enhancer element give only partial interference in
this assay with NF-KB induced in pre-B cells (7) and the 3T3
factor yields complete interference at all four guanines (Fig.
3). Thus, we cannot say conclusively whether the major
inducible 3T3 factor is identical to that of NF-KB in other cell
types but, as we noted above, 3T3 cells contain mRNA that
is recognized by authentic NF-KB probe, and this mRNA is
induced following serum growth factor stimulation. Further-
more, a second inducible factor (complex III) is detected
that generates a DNA-protein complex similar in mobility to
purified KBF1 (5) and has binding properties similar to or
identical those of the inducible NF-KB like activity. The
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identity of this factor is unknown, but it is likely to be related
to NF-KB since its DNA-binding activity is inhibited by lKB
(Fig. 2C).
Experiments demonstrate that the NF-KB DNA-binding
activity is transiently induced in quiescent 3T3 cells follow-
ing treatment with serum; the activity is at or near maximal
levels following only 30 min of treatment and remains
relatively high until at least 6 h of treatment. By 12 h, the
DNA-binding activity has returned to much lower levels.
Interestingly, we cannot detect the NF-KB-like activity in
nuclear extracts of proliferating 3T3 cells (Fig. 4), although
NF-KB activity is detected in deoxycholate-treated cytoplas-
mic extracts (data not shown). However, we detect elevated
levels of this DNA-binding activity at least 6 h following
serum stimulation, which is well into the initial G1 phase.
The cell cycle of the 3T3 cells used in this study is approx-
imately 24 h, with a G, period of approximately 12 to 14 h
(70). Thus, if NF-KB were expressed during an equivalent
period of the G1 period in cycling cells, we should be able to
detect its activity in nuclear extracts of proliferating cells.
Thus, it may be that NF-KB is induced only as cells leave the
quiescent state (Go) and would not be detected in cycling
cells. Since we (Fig. 4) and others (59) have not detected any
nuclear DNA-binding activity in proliferating 3T3 cells, we
favor the view that NF-KB is expressed only in the Go-to-G1
transition. It is also possible that NF-KB is expressed in
cycling cells, but in such small quantities or in such a narrow
time frame that we cannot detect it in our gel mobility shift
assays.
The inducibility of the NF-KB-like activities during the
Go-to-G1 transition suggests that these factors play a role in
control of expression of genes not strictly involved in
immune function. A role for NF-KB in cell growth is sug-
gested by several observations. One observation suggesting
that NF-KB plays a role in T-cell growth is that the human
T-cell lymphotropic virus type I tax gene product induces
NF-KB DNA-binding activity (8, 44, 57). This virus is
strongly implicated in T-cell leukemia, and thus tax activa-
tion may contribute to leukemogenesis by the activation of
NF-KB, with the subsequent transcriptional stimulation of
the interleukin-2 receptor gene. Recently, it has been dem-
onstrated that tumor necrosis factor alpha has growth factor-
like effects on quiescent 3T3 cells (19). Since this cytokine
has been shown to induce NF-KB (46, 52), it may be that
NF-KB is responsible for its growth stimulatory effects.
NF-KB is also implicated in cell growth by the observation
that the v-rel oncogene product, which is related to NF-KB,
can bind a functional NF-KB target site and inhibit its
function (9). The assumption here is that the transforming
potential of v-rel is based on its ability to block normal
NF-KB function. Finally, NF-KB binds and regulates expres-
sion of the 31-interferon gene (23, 43, 67), and interferons
have been shown to have negative growth effects on certain
cells (references 25 and 54 and references within). The latter
two observations would be consistent with a role for NF-KB
in negative growth control, while the first two would be
consistent with a positive growth role. Thus, in addition to a
role in the transcriptional regulation of genes involved in
immune function (42), NF-KB may regulate the expression of
certain genes involved in growth control.
Interestingly, both of the inducible NF-KB-like factors
bind to an element found some 1,100 bp upstream of the P1
transcription start site of the c-myc gene (Fig. 2A). This site
was initially identified as a sequence capable of interacting
with NF-KB-like factors found in WEHI 231 cells (22).
Changes in NF-KB interactions with this sequence were
noted upon growth arrest of these cells with anti-immuno-
globulin treatment. c-myc expression is inducible by serum
growth factor treatment of quiescent 3T3 cells (29). Although
c-myc gene expression is complex (10, 37, 47, 63), it is
tempting to speculate that NF-KB may play a role in the
control of myc gene expression during the Go-to-G1 transi-
tion. It has been demonstrated that c-myc expression is
inducible by LPS, cycloheximide, platelet-derived growth
factor, and phorbol ester treatment of cells (38), and each of
these reagents has been shown to induce NF-KB (5, 60).
Experiments presented in Fig. 5B demonstrate that the
c-myc NF-KB binding site confers serum growth factor
inducibility on a minimal heterologous promoter. Thus,
NF-KB may directly regulate c-myc gene expression follow-
ing serum growth factor stimulation of quiescent 3T3 cells.
Mudryj et al. (47) have demonstrated that another candidate
regulator of serum growth factor inducibility of the c-myc
gene is the factor E2F. E2F is inducible approximately
fourfold by serum treatment of quiescent cells but binds
much closer to the c-myc P1 promoter than does NF-KB.
The sequence TGGGGATTCCCCA found in the class I
MHC enhancer confers growth inducibility on a minimalfos
promoter (Fig. 5). Since we detect only the NF-KB activities
as being serum inducible, we believe that these factors are in
fact transcriptionally activating gene expression through the
MHC enhancer element. Interestingly, we find that a con-
struct that contains two copies of the highly related NF-KB
site found in the immunoglobulin kappa enhancer is not
inducible in serum-stimulated 3T3 cells (36). This construct
is inducible in a pre-B-cell line when these cells are stimu-
lated with LPS (53). Thus, it is not clear whether the
NF-KB-like activity that we have detected in 3T3 cells is
incapable of transcriptionally activating the kappa enhancer
construct and is therefore a different NF-KB from that in B
cells, whether some factor is missing in 3T3 cells that is
required for expression mediated by the kappa element, or
whether it is actually some other undetected factor (not
NF-KB) that activates expression through the class I MHC
enhancer and c-myc elements in 3T3 cells.
NF-KB is found in the cytoplasm of a wide variety of cell
and tissue types, where it is associated with an inhibitor
protein, IKB. Activation of NF-KB DNA-binding activity is
associated with the phosphorylation of IKB (26, 62). NF-KB
binding activity can be induced by interleukin-1, tumor
necrosis factor alpha, and double-stranded RNA, by mito-
genic stimulation of pre-B and Jurkat T cells, and by phorbol
ester (11, 20, 23, 34, 42, 46, 49, 52, 60, 61). Most of these
stimuli are known to activate protein kinases, consistent
with the activation of nuclear NF-KB DNA-binding activity
upon phosphorylation of IKB (26). Serum growth factor
treatment of quiescent cells results in the activation of
tyrosine kinases, hydrolysis of phosphatidylinositol, alter-
ations in pH, increases in cytosolic calcium levels, and
elevation of cyclic AMP, which results in activation of
protein kinase C and cyclic AMP-activated kinases (68).
Thus, activation of protein kinases by serum growth factor
treatment of quiescent cells may lead to phosphorylation of
IKB and the subsequent relocalization of NF-KB DNA-
binding activity to the nucleus. The localization of NF-KB in
the cytoplasm of serum-arrested cells makes it an ideal
candidate for an immediate-early response factor in the
growth response. Our demonstration that induction of
NF-KB nuclear DNA-binding activity is near maximal fol-
lowing only 30 min of serum stimulation and does not require
protein synthesis is consistent with this idea. These results
establish a potential role for NF-KB in signal transduction,
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linking engagement of growth factor receptors by specific
protein ligands with regulation of specific gene expression.
The induction of expression of an NF-KB DNA-binding
activity by serum growth factor treatment of growth-arrested
3T3 cells and the lack of similar expression in proliferating
cells suggest a direct role for this transcription factor in the
Go-to-G1 transition.
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